Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 59

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 59
---
for FAP. With respect to tolimidone, teplizumab, the first disease-modifying treatment of Type 1 diabetes, or T1D, has been approved for
the delay of Stage 3 T1D and a number of companies are researching potentially disease-modifying approaches to T1D including stem cell
therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing an immunotherapeutic.
In addition, the JDRF T1D Fund has invested in approximately 30 private companies working on a variety of approaches to the treatment
of T1D. With respect to MTX110, there are a number of companies researching potential therapeutic treatments of GBM including CNS Pharmaceuticals,
Inc. and Plus Therapeutics, Inc. Chimerix Inc. is among a number of companies developing a product for DMG.

Some of these competitive
products and therapies are based on scientific approaches that are the same or similar to our approach, and others are based on entirely
different approaches. Potential competitors also include academic institutions, government agencies and other public and private research
organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing
and commercialization.

Our competitors in the biotechnology
and pharmaceutical industries may have superior research and development capabilities, products, manufacturing capability or sales and
marketing expertise. Many of our competitors may have significantly greater financial and human resources and may have more experience
in research and development.

As a result of these factors,
our competitors may obtain regulatory approval of their products more rapidly than we are able to or may obtain patent protection of other
intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop
products that are more effective, more widely used and less costly than our own product candidates, and may be more successful in commercializing
their products.

We anticipate that we will
face increased competition in the future as new companies enter our markets and alternative products and technologies become available.
Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among
a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining
qualified scientific, management and commercial personnel, as well as in acquiring technologies complementary to, or necessary for, our
programs.

Changes